The new VivoTag 645 represents VisEn’s first agent offering in the lower-red wavelengths, enabling optimized and integrated imaging applications in both in vivo and in vitro research areas. The VivoTag 645 is specifically designed for efficient and robust labeling of biomolecules, and is optimized for broad in vitro and in vivo imaging performance, including system compatibility, superior brightness, biocompatibility and stability in biological environments.
"Our new VivoTag 645 represents an important evolution in our fluorescent imaging agent product line," said Kirtland Poss, President and CEO of VisEn Medical. "This new label is designed to be well-suited for applications both in vitro and in vivoresearch and we look forward to working closely with our customers in continually advancing these integrated research areas".
The new VivoTag 645 is particularly well suited for labeling and imaging of proteins, antibodies, and small molecules in a range of research areas. The fluorescence wavelength is matched for biological imaging applications on in vitro and in vivofluorescence systems, including advanced microscopes, high content imaging and flow cytometry systems. It is also optimized for use with VisEn’s fluorescence tomography FMTTM imaging systems which also have expanded wavelength capabilities to enable quantitative imaging of up to four channels and four different biomarkers of interest in vivo.
VisEn’s proprietary fluorescence imaging agents and labels are designed to provide the industry’s broadest and most robust range of biologically-specific imaging readouts. VisEn offers over 35 different fluorescence molecular agents for imaging key disease-associated biologic targets, processes and pathways. VisEn agent brands include ProSense®, IntegriSenseTM, AngioSenseTM, OsteoSense®, MMPSenseTM, GastroSenseTM, ReninSenseTM, Annexin-VivoTM, and the FASTTM line of imaging agents including Cat K FASTTM and Cat B FASTTM. VisEn also offers specialized lines of agent labeling platforms, including its proprietary VivoTag® fluorescence labeling dyes and its NanoSpark® nanoparticles for customized fluorescence agent labeling.
They are all designed and optimized specifically for superior biocompatibility, brightness, stability and performance in biological imaging applications including in vitro, cell, tissue and in vivo imaging applications.
All VisEn agents and labels are designed for in vivo biomarker quantification using VisEn’s Fluorescence Molecular Tomography (FMT) imaging systems, or for general use along with other non-quantitative fluorescence in vivo imaging systems. VisEn agents are also designed to enable complementary in vitro biomarker readouts in cells and tissues using standard fluorescence microscopy and other cellular-based imaging systems. With a focus on translational research and results, all of VisEn’s technologies are designed to generate translational data linking preclinical research into clinical medicine.
About VisEn Medical Inc.
VisEn’s in vivo fluorescence imaging technologies, including its Fluorescence Agent Portfolio and its Fluorescence Molecular Tomographic (FMTTM) Imaging Systems provide robust fluorescence molecular imaging performance in identifying, characterizing and quantifying ranges of disease biomarkers and therapeutic efficacy in vivo. VisEn’s FMT systems and agents are used by leading research institutions and pharmaceutical companies in applications including cancer research, inflammation, cardiovascular, skeletal and pulmonary disease. The Company also works with large pharmaceutical partners to design ranges of tailored molecular imaging agents and applications that are designed to their specific pre-clinical and clinical research areas.For more information visit www.visenmedical.com .
VisEn Medical Inc.
45 Wiggins Avenue
Bedford, MA 01730